Biota Holdings Limited (ASX:BTA) and AstraZeneca (LON:AZN) today announced that the 2005 Collaboration and License Agreement with MedImmune has been assigned to AstraZeneca. AstraZeneca has also secured the rights to a number of Asian and Pacific territories not held by MedImmune under the original agreement and for which Biota will receive an additional US$3.5 million payment, plus future royalties.
Australian regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its allogeneic, or "off-the-shelf", cell therapy product was safe and highly effective in preclinical trials for interbody fusion of the cervical spine in the neck.
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the start of its next clinical trial of VivaGel(R). The study will measure the level of antiviral activity retained by VivaGel(R) after vaginal administration. Assessment will be by laboratory assay of vaginal samples collected up to 24 hours after VivaGel(R) application. The study in 12 women will determine the timescale over which VivaGel(R) retains activity against HIV and HSV-2 (genital herpes).
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced successful preclinical trial results which showed that its proprietary adult stem cells regenerated and regrew damaged knee cartilage in post-menopausal osteoarthritis.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced the commencement of dosing in the first Phase IIa challenge study of BTA798, an orally delivered and potent inhibitor of human rhinovirus (HRV). HRV is the major cause of the common cold and is associated with clinical complications for patients with asthma, cystic fibrosis, chronic obstructive pulmonary disease or a compromised immune function.
Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) was granted in New Zealand.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today confirmed that national news items broadcast yesterday on the ABC, Channel 9 and Channel 10 focused on results of its adult stem cell bone fracture repair trial conducted at The Royal Melbourne Hospital.
